research 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
Search
for
Sort by
Research
510-540 / 1000+ results
research JAK Inhibitors in the Treatment of Alopecia Areata: Efficacy, Safety, and Long-term Outcomes
JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.
research Pustular Eruption in a Patient Treated With Trametinib
Trametinib can cause skin issues, but they can often be managed without stopping the drug.
research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research Trichoscopic evaluation in oral tofacitinib and oral betamethasone in the treatment of moderate to severe alopecia areata
Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
research Ruxolitinib for the treatment of severe alopecia areata
Ruxolitinib can help regrow hair in severe alopecia areata.
research Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
Aumolertinib effectively controls lung cancer and improves quality of life.
research Hairy tongue associated with the use of baricitinib therapy for ophiasis pattern alopecia areata
A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.
research Treatment of alopecia areata in pre‐adolescent children with oral tofacitinib: A retrospective study
Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
research Clinical response to adjunctive platelet-rich plasma injections in a patient with alopecia universalis on oral tofacitinib
A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.
research Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
Baricitinib works better in adolescents than adults for treating severe alopecia areata.
research 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata
Baricitinib is effective and safe for treating alopecia areata.
research Anticancer activity of cepharanthine on non-small cell lung cancer cells
Cepharanthine shows promise as a potential lung cancer treatment by effectively killing cancer cells.
research A Study on the Role of Tofacitinib Among Patients Treated with Alopecia Areata
Tofacitinib effectively treats Alopecia Areata.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Bletilla striata polysaccharide-based dissolving microneedle patch integrated with nanoparticles for promoting hair regrowth
A new microneedle patch effectively promotes hair regrowth with less frequent dosing.
research Efficacy and safety of baricitinib in patients with refractory alopecia areata
Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.
research A meta-analysis of the effectiveness and safety of Sintilimab combined with chemotherapy in the trea tment of advanced non-small cell lung cancer
Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.
research Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
research P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib was more effective than methotrexate for treating alopecia areata.
research Janus kinase (JAK)
JAK inhibitors may help treat alopecia areata and promote hair regrowth.
research Epidermal growth factor receptor inhibitor Geftinib-induced erosive pustular dermatosis of the scalp – A report with a brief review of the literature
Gefitinib can cause scalp skin issues and permanent hair loss.
research Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
research 448 Challenges of securing insurance approval for oral tofacitinib treatment of alopecia areata: A multi-institutional retrospective review
Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.